company background image
SYBX

Synlogic NasdaqGM:SYBX Stock Report

Last Price

US$1.09

Market Cap

US$76.6m

7D

5.8%

1Y

-60.2%

Updated

15 Aug, 2022

Data

Company Financials +
SYBX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SYBX Stock Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States.

Synlogic, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Synlogic
Historical stock prices
Current Share PriceUS$1.09
52 Week HighUS$4.04
52 Week LowUS$0.83
Beta1.32
1 Month Change10.09%
3 Month Change-6.03%
1 Year Change-60.22%
3 Year Change-77.43%
5 Year Changen/a
Change since IPO-90.97%

Recent News & Updates

Aug 10

Synlogic Q2 2022 Earnings Preview

Synlogic (NASDAQ:SYBX) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.23 (+17.9% Y/Y) and the consensus Revenue Estimate is $0.12M (-40.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Aug 09
Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Jul 12

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Synlogic (NASDAQ:SYBX) said the first healthy volunteer was dosed in a phase 1 trial of its oral therapy SYNB1353 designed to consume an amino acid called methionine for potentially treating homocystinuria (HCU). HCU is rare condition which interferes with the body's ability to break down the amino acid methionine. The condition is characterized by an excess of the compound homocysteine in the urine and blood thereby causing  thromboembolism, lens dislocation, skeletal abnormalities, developmental delay, and intellectual disability. The company said SYNB1353 is designed to consume methionine, with the goal of lowering homocysteine levels in patients with HCU, thus lowering the risk of serious and debilitating complications. "We are delighted to continue to advance our pipeline of programs with today's announcement, a notable milestone as we continue towards three expected clinical readouts in 2022, and a reflection of the productivity of the Synthetic Biotic platform,” said Synlogic President and CEO Aoife Brennan.

Shareholder Returns

SYBXUS BiotechsUS Market
7D5.8%1.4%3.6%
1Y-60.2%-19.6%-9.6%

Return vs Industry: SYBX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: SYBX underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is SYBX's price volatile compared to industry and market?
SYBX volatility
SYBX Average Weekly Movement13.1%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: SYBX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SYBX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a84Aoife Brennanhttps://www.synlogictx.com

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma.

Synlogic, Inc. Fundamentals Summary

How do Synlogic's earnings and revenue compare to its market cap?
SYBX fundamental statistics
Market CapUS$76.55m
Earnings (TTM)-US$62.64m
Revenue (TTM)US$1.90m

40.2x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SYBX income statement (TTM)
RevenueUS$1.90m
Cost of RevenueUS$0
Gross ProfitUS$1.90m
Other ExpensesUS$64.55m
Earnings-US$62.64m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.89
Gross Margin100.00%
Net Profit Margin-3,290.13%
Debt/Equity Ratio0%

How did SYBX perform over the long term?

See historical performance and comparison